Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. Tsuboi M, Herbst RS, John T, Kato T, et al. N Engl J Med 2023 Jun 4. doi: 10.1056/NEJMoa2304594.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tsuboi M, Herbst RS, John T, Kato T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med 2023 Jun 4. doi: 10.1056/NEJMoa2304594.
PMID: 37272535